Date: 2013-11-04
Type of information: R&D agreement
Compound: new drugs to treat Gram-negative bacterial infections
Company: AstraZeneca (UK) Agency for Science, Technology and Research (A*STAR) (Singapore)
Therapeutic area: Infectious diseases
Type agreement: R&D
licensing
commercialisation
Action mechanism:
Disease: Gram-negative bacterial infections
Details: * On November 4, 2013, two units under Singapore’s Agency for Science, Technology and Research (A*STAR), the Experimental Therapeutics Centre (ETC) and Exploit Technologies Pte Ltd (ETPL) have signed a joint research collaboration agreement with AstraZeneca, to develop new drugs to treat Gram-negative bacterial infections. Under the agreement, AstraZeneca and ETC will collaborate on joint research projects, with ETC contributing expertise in the discovery and optimization of lead compounds, and AstraZeneca providing expertise in antimicrobial drug discovery. The three-and-a-half-year collaboration focuses on generating high quality preclinical development candidates for entry into clinical studies. The agreement also covers commercialisation and licensing of any arising intellectual property.
Financial terms:
Latest news:
